Clinical impact of direct-acting antiviral treatment on patients with hepatitis C virus–related oral lichen planus

Stasio, Dario Di; Petrillo, Marco Di; Romano, Antonio; Fiori, Fausto; Russo, Diana; Adinolfi, Luigi Elio; Lucchese, Alberta; Serpico, Rosario; Marrone, Aldo

doi:10.1016/j.oooo.2020.10.040

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Different case series on the effects of HCV-clearance by DAA on LP have been published. The data of these studies have shown that, after treatment with DAAs, 82% of cases show a resolution of or improvement in the disease, although some cases may relapse [128,129].…”

Section: Hcv and Licken Planus (Lp)mentioning

confidence: 99%

A Review on Extrahepatic Manifestations of Chronic Hepatitis C Virus Infection and the Impact of Direct-Acting Antiviral Therapy

Mazzaro

Quartuccio

Adinolfi

et al. 2021

Viruses

Self Cite

View full text Add to dashboard Cite

Extrahepatic manifestations are a feature of chronic hepatitis C virus (HCV) infection. In the course of chronic HCV infection, about 70% of patients have one or more extrahepatic manifestations. The latter are often the first and only clinical sign of infection. Experimental and clinical data support a causal association for many extrahepatic manifestations and HCV infection, which include mixed cryoglobulinemia, non-Hodgkin lymphomas (NHL), cardiovascular disease, insulin resistance, type 2 diabetes, neurological and psychiatric disease and other rheumatic diseases. All these extrahepatic conditions influence the morbidity, quality of life and mortality of HCV-infected patients. Currently, interferon-free therapeutic regimens with direct-acting antiviral agents (DAA) offer the possibility of treatment to almost the entire infected population, irrespective of stage of cirrhosis and associated serious comorbidities, always maintaining a high efficacy and tolerability. Several studies have shown a close association between HCV clearance by DAAs and an improvement or reduction in the risk of extrahepatic manifestations. Patients with HCV after a sustained virologic response (SVR) by DAA treatment have a lower risk than non-responders of developing cryoglobulinemic vasculitis and B-cell non-Hodgkin’s lymphomas. Furthermore, the SVR by DAA also reduces the risk of acute coronary syndrome, cardiovascular disease, insulin resistance and type 2 diabetes, and it improves atherosclerosis. HCV clearance by DAA also improves the quality of life and survival of patients with chronic HCV infection with associated extrahepatic diseases. Thus, DAAs should be initiated as early as possible in HCV patients with extrahepatic manifestations.

show abstract

Section: Hcv and Licken Planus (Lp)mentioning

confidence: 99%